- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06047379
Bezpieczeństwo i skuteczność NEO212 u pacjentów z gwiaździakiem z mutacją IDH, glejakiem wielopostaciowym IDH typu dzikiego lub przerzutami do mózgu
Otwarte badanie fazy 1/2 dotyczące ustalania dawki, bezpieczeństwa i skuteczności doustnego NEO212 u pacjentów z gwiaździakiem z mutacją IDH, glejakiem wielopostaciowym IDH typu dzikiego lub niekontrolowanymi przerzutami do mózgu u pacjentów z wybranymi guzami litymi.
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain.
The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Przegląd badań
Status
Warunki
- Czerniak
- Rak nerkowokomórkowy
- Rak szyjki macicy
- Rak Drobnokomórkowy Płuc
- Rak żołądka
- Rak jelita grubego
- Rak przełyku
- Niedrobnokomórkowego raka płuca
- Rak płaskonabłonkowy głowy i szyi
- Rak płaskonabłonkowy przełyku
- Rak urotelialny
- Rak z komórek Merkla
- Gruczolakorak połączenia żołądkowo-przełykowego
- Przerzuty do mózgu, dorośli
- Rak kolczystokomórkowy
- Glejak wielopostaciowy, IDH typu dzikiego
- Rozlany gwiaździak, mutant IDH
- Niedopasowana naprawa niedoboru raka jelita grubego
- Niestabilność mikrosatelitarna - guz złośliwy o wysokiej zawartości ciał stałych
- Niedopasowanie Naprawa Niedobór litego guza złośliwego
- Niestabilność mikrosatelitarna – wysoki poziom raka jelita grubego
Szczegółowy opis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Phase 1 is a standard cohort dose escalation 3+3 design with a modified Fibonacci dose escalation used to determine the maximum tolerated dose to select a recommended Phase 2 dose (RP2D) of NEO212 for Phase 2a and Phase 2b. The initial dose of NEO212 will be 170 mg and the dose will increase in successive cohorts (220, 400, 610, 810, and 1,000 mg) until a MTD is reached and a RP2D is selected. There will be up to 42 patients enrolled in Phase 1. In the event two DLTs are experienced in any cohort, a dose de- escalation cohort will be followed (with half of the dose increase from the previous cohort) to determine the MTD/RP2D.
Phase 2a is a safety run-in study with a standard 3+3 design used to confirm the safety of the MTD/RP2D of NEO212 when given in combination with select SOC regimens for patients with uncontrolled metastases to the brain. There will be up to 12 patients enrolled into each combination regimen to confirm safety. One dose below the NEO212 MTD/RP2D Cohort Dose will be administered as a starting dose to establish safety (3+3), before moving to Phase 2b with the MTD/RP2D (3+3). In the event that two DLTs are experienced for patients receiving the MTD/RP2D in combination with SOC, the dose de-escalation cohort will be expanded to determine the MTD for a newly established Phase 2b Treatment Group.
Phase 2b is a dose expansion study to assess efficacy of NEO212 alone, at the MTD/RP2D in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype as a single Treatment Group. A second Treatment Group to study the MTD/RP2D of NEO212 in combination with select SOC regimens in patients with solid tumors and uncontrolled metastases to the brain established in Phase 2a will be evaluated. Phase 2b will be initiated for patients with Astrocytoma IDH-mutant or Glioblastoma IDH-wildtype alongside Phase 2a. There will be up to 28 patients enrolled to have 27 evaluable patients enrolled in each Phase 2b Treatment Group.
For all phases of the study, NEO212 will be self-administered daily for days 1-5 of a 28- day treatment cycle.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Chloe Richmond
- Numer telefonu: 224 218 2408
- E-mail: chloe@anovaevidence.com
Kopia zapasowa kontaktu do badania
- Nazwa: Christopher Beardmore
- Numer telefonu: 224 218 2408
- E-mail: chris@anovaevidence.com
Lokalizacje studiów
-
-
California
-
Beverly Hills, California, Stany Zjednoczone, 90212
- Rekrutacyjny
- Precision NextGen Oncology
-
Główny śledczy:
- Kamlesh Sankhala, MD
-
Kontakt:
- Jing Liu, MD MA
- Numer telefonu: (424) 777-0708
- E-mail: JingL@nextgenonc.com
-
Glendale, California, Stany Zjednoczone, 91203
- Rekrutacyjny
- OPN Healthcare, Inc
-
Główny śledczy:
- Vu Phan, MD
-
Kontakt:
- Heather Lyon
- E-mail: heatherl@opnhc.com
-
Los Angeles, California, Stany Zjednoczone, 90033
- Rekrutacyjny
- University of Southern California
-
Główny śledczy:
- Frances Chow, MD
-
Kontakt:
- Sandy Tran
- Numer telefonu: (323) 865-3980
- E-mail: Sandy.Tran@med.usc.edu
-
-
Florida
-
Boynton Beach, Florida, Stany Zjednoczone, 33426
- Rekrutacyjny
- MDR Core Network
-
Główny śledczy:
- Robert Levin, MD
-
Kontakt:
- Ismaray Hernandez
- E-mail: ismaray@mdrcore.com
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 21111
- Rekrutacyjny
- Tufts Medical Center
-
Kontakt:
- Christian Lawlor
- E-mail: Christian.Lawlor@tuftsmedicine.org
-
Kontakt:
- Soma Sengupta, MD
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Rekrutacyjny
- Vanderbilt University Medical Center
-
Główny śledczy:
- Alexander Mohler, MD
-
Kontakt:
- Amanda Nolen
- E-mail: amanda.nolen@vumc.org
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75246
- Rekrutacyjny
- Baylor, Scott and White Research Institute
-
Kontakt:
- Tarah Satterfield
- E-mail: Tarah.Satterfield@bswhealth.org
-
Główny śledczy:
- Divya Mella, MD
-
-
Washington
-
Tacoma, Washington, Stany Zjednoczone, 98405
- Rekrutacyjny
- Northwest Medical Specialties
-
Główny śledczy:
- Jorge Chaves, MD
-
Kontakt:
- Sheila Marsh
- Numer telefonu: 253-380-8173
- E-mail: smarsh@nwmsonline.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patient must be ≥ 18yrs of age.
-
Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
-
Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
-
Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
-
If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
-
Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60.
-
Patient with select solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
-
Patient must have an expected survival or at least three months.
-
Patient must have a baseline MRI of the brain with gadolinium within 14 days of administration of NEO212.
-
Patient with select solid tumors must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
-
Patients must be able to comply with all study assessments.
-
If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
-
Patient must have adequate organ and marrow function as follows:
- Absolute neutrophil count ≥ 1,500/microliter
- Platelets ≥ 100,000/microliter
- Total bilirubin within normal institutional limits
- AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
- Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24- hour urine collection).
-
Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
- A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
- A serum pregnancy test will be repeated immediately if pregnancy is suspected.
Phase 1: (dose escalation)
-
Patient must:
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patients receiving prior systemic therapy must have a minimum wash-out period (defined as the period prior to receipt of the first dose of NEO212) of:
- 28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;
- 2 weeks from administration of immunotherapies;
- 28 days from administration of cytotoxic agents; and
- 7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine).
NOTE: No washout is necessary for alternating electrical fields.
Phase 2a: (safety run-in)
- Patient must have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
- Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
- Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria.
- Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
Phase 2b: (efficacy)
-
Patient must:
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
-
Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria
-
Patient with select solid tumors must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
-
Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection). Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
Exclusion Criteria: (all Phases)
- Patient in Phase 1 concurrently receiving any other antitumor therapy.
- Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
- Patients with metastases to the spinal cord parenchyma.
- Patients with metastases to the meninges.
- Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
- Patient with history of known leptomeningeal involvement.
- Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
- Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec, a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and/or the use of concomitant medications that prolong QT/QTc interval.
- Patient had surgery within 7 days prior to the date of informed consent.
- Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.
- Patient had prior treatment with perillyl alcohol.
- Patient has a history of allergic reactions attributed to perillyl alcohol.
- Patients in Phase 2b with Astrocytoma IDH-mutant, or Glioblastoma IDH-wildtype who have had more than one recurrence or progression of his/her primary CNS tumor(s).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Phase 2a Safety Run-In - NEO212 and Ipilimumab
- Unresectable or metastatic melanoma with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Inne nazwy:
|
|
Eksperymentalny: Phase 2a Safety Run-In - NEO212 and Pembrolizumab
The following primary cancers with uncontrolled metrastases to the brain:
NEO212 - Same as Arm 1. Pembrolizumab - 200 mg administered every 3 weeks per package insert. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Inne nazwy:
|
|
Eksperymentalny: Phase 2a Safety Run-In - NEO212 and Nivolumab
The following primary cancers with uncontrolled metrastases to the brain:
NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Nivolumab - 240 mg administered every 2 weeks per package insert |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Inne nazwy:
|
|
Eksperymentalny: Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib)
- Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Inne nazwy:
|
|
Eksperymentalny: Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol)
- Colorectal cancer (CRC) with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert. Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Inne nazwy:
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Inne nazwy:
|
|
Eksperymentalny: Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin)
- Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks. Bevacizumab - 10 mg/kg IV every 2 weeks. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Inne nazwy:
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Inne nazwy:
|
|
Eksperymentalny: Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype
Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
|
|
Eksperymentalny: Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain
Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Inne nazwy:
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Inne nazwy:
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Inne nazwy:
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Inne nazwy:
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Inne nazwy:
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Inne nazwy:
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Inne nazwy:
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Inne nazwy:
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain
Ramy czasowe: 6 months
|
As determined by incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0 |
6 months
|
|
Phase 1: Identify the maximum tolerated dose (MTD) of NEO212
Ramy czasowe: 6 months
|
Maximum Tolerated Dose of NEO212 as determined by the dose escalation rules. |
6 months
|
|
Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212
Ramy czasowe: 6 months
|
Determine the recommended Phase 2 dose (RP2D) of NEO212 |
6 months
|
|
Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain
Ramy czasowe: 6 months
|
Determined by incidence and severity of adverse events determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0). |
6 months
|
|
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.
Ramy czasowe: 6 months
|
Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype. |
6 months
|
|
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.
Ramy czasowe: 6 months
|
Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors (see Appendix 2) with uncontrolled metastases to the brain. |
6 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Krzesło do nauki: Tom Chen, MD, PhD, NeOnc Technologies
- Dyrektor Studium: Josh Neman, PhD, NeOnc Technologies Holdings, Inc.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby nerek
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby jelit
- Infekcje
- Choroby wirusowe
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby żołądka
- Nowotwory jelit
- Choroby odbytu
- Choroby macicy
- Choroby narządów płciowych, kobiety
- Choroby płuc
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Choroby okrężnicy
- Infekcje wirusami DNA
- Choroby przełyku
- Nowotwory płuc
- Nowotwory narządów płciowych, kobiety
- Choroby skórne
- Nowotwory urologiczne
- Rak
- Nowotwory, płaskonabłonkowy
- Choroby szyjki macicy
- Glejak
- Nowotwory neuroepitelialne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Nowotwory Układu Nerwowego
- Nowotwory nerek
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Nowotwory macicy
- Guzy neuroendokrynne
- Zakażenia wirusem nowotworowym
- Nevi i czerniaki
- Nowotwory skóry
- Zakażenia poliomawirusem
- Rak, neuroendokrynny
- Choroby skóry i tkanki łącznej
- Rak płaskonabłonkowy głowy i szyi
- Rak płaskonabłonkowy przełyku
- Nowotwory żołądka
- Nowotwory jelita grubego
- Nowotwory przełyku
- Rak, płaskonabłonkowy
- Glejaka wielopostaciowego
- Rak, Komórka Nerki
- Rak, płuco niedrobnokomórkowe
- Nowotwory szyjki macicy
- Rak Drobnokomórkowy Płuc
- Czerniak
- Nowotwory mózgu
- Rak, komórka przejściowa
- Gwiaździak
- Nowotwory ośrodkowego układu nerwowego
- Rak, Komórka Merkla
- Aminokwasy, peptydy i białka
- Białka
- Organiczne chemikalia
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Kompleksy koordynacyjne
- Taksoidy
- Cyklodekan
- Diterpenes
- Niwolumab
- Bewacyzumab
- Ipilimumab
- Karboplatyna
- Paklitaksel
- pembrolizumab
- regorafenib
- aflibercept
- Protokół IFL
- NEO212
Inne numery identyfikacyjne badania
- NEO212-01
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .